MicroTransponder Inc. is a medical device company developing neurostimulation technology to restore neurological function in patients with chronic conditions. The company's core innovation is the Paired Vagus Nerve Stimulation (Paired VNS™) System, which synchronizes vagus nerve stimulation with rehabilitation exercises to help stroke survivors regain arm and hand motor function. This pairing approach - timing electrical stimulation to specific therapeutic movements - represents a shift from passive neuromodulation to active, rehabilitative intervention.
The company's flagship product, the Vivistim System, has received FDA approval and targets stroke survivors experiencing upper limb impairment. The technology stems from decades of neuroscience research into how neuromodulation can enhance neuroplasticity during rehabilitation therapy. While stroke recovery is the approved indication, the company is exploring applications in tinnitus and chronic pain, suggesting the underlying platform may generalize across neurological conditions that respond to vagus nerve stimulation paired with behavioral therapy.
MicroTransponder operates in the neuromodulation sector, which sits at the intersection of medical devices, neuroscience research, and rehabilitation technology. The company is headquartered in the United States and led by CEO Richard Foust. The development trajectory - described as years of building the Paired VNS System - reflects the regulatory complexity and clinical validation required for implantable neurostimulation devices. As with any medical device company handling patient data and connected therapeutic systems, the organization operates within strict regulatory frameworks that govern data security, device integrity, and patient privacy.